Acquisitions & Expansion Boost Marimed's Q4 Revenue 6% Sequentially, 2022 Sales Increased To $134M

MariMed, Inc. MRMD announced its financial results Wednesday afternoon for the fourth quarter and full year ended December 31, 2022. The company reported sales for the year increased to $134 million, compared with $121.5 million the prior year. Net income nearly doubled to $13.5 million in 2022 from $7.2 million the previous year.

“I am pleased to report that our fourth quarter revenue grew sequentially and year-over-year as we continued to outperform the industry in all of our key states,” said MariMed CEO Jon Levine, who will speak at the April 11-12 Benzinga Cannabis Capital Conference in Miami.

“Headwinds continued to challenge the industry, and the economy impacted consumer spending, yet MariMed delivered strong financial results, including positive cash flows from operations for the third consecutive year," Levine continued. "Our balance sheet strength, coupled with our outstanding retail and wholesale operations, high-quality and innovative product portfolio, and exceptional customer service, should fuel accelerated growth in 2023 and beyond.”

With sales up 15% year-over-year to $35.8 million for Q4, Marimed recorded a net income of $4.8 million in the period, compared with a net loss of $6.4 million last year.

The company forecast revenue in excess of $150 million for 2023, driven partly by continuing the acquisition activity underway this year. Marimed noted in a news release that it expects to open four new dispensaries by the end of 2023, one each in Illinois and Ohio and two in Massachusetts along with wholesale facilities in Illinois and Missouri. 

Revenue and adjusted EBITDA are projected to grow over the course of the year as these new facilities become operational. Unlike many companies that are laying off workers, MariMed anticipates significant increases to its headcount in 2023 ahead of these new and expanded assets coming online.

In Jan. 2023, Marimed secured $35 million via a secured credit facility with Chicago Atlantic as the lead lender. The funding is critical to support Marimed’s continued expansion and growth plans, as it had just $9.7 million in cash and cash equivalents at the end of a year that started with $29.7 million on hand.

The Benzinga Cannabis Capital Conference Is Back!

Come and meet MariMed's CEO Jon Levine in person as well as other cannabis entrepreneurs at the most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference. This is the place where DEALS GET DONE, where money is raised, M&A start, and companies meet investors and key partners. Stay with us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Secure your tickets now before prices go up.


Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsPenny StocksSmall CapEventsAfter-Hours CenterMarketsBenzinga Cannabis Capital ConferenceJon LevineMariMed earnings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!